Mechanism, dosage tables, oral vs SubQ protocols, preclinical fat loss data, stacking with Retatrutide and AOD-9604, and COA-verified vendor pricing.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective small molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme that consumes nicotinamide (a NAD+ precursor) and S-adenosylmethionine (SAM), the universal cellular methyl donor. Overexpression of NNMT in adipose tissue is associated with obesity and impaired metabolic function. By inhibiting NNMT, 5-Amino-1MQ restores NAD+ precursor availability and SAM levels, increasing mitochondrial activity and fat oxidation in adipose tissue.
| Property | Value |
|---|---|
| Chemical class | Quinolinium derivative (small molecule, not a peptide) |
| Molecular weight | ~174 Da |
| Target enzyme | Nicotinamide N-methyltransferase (NNMT) |
| Key downstream effects | โ NAD+, โ SAM, โ adipogenesis, โ fat oxidation |
| Routes | Oral, subcutaneous injection |
| Oral bioavailability | Good (small molecule advantage over peptides) |
| Storage | Cool, dry, away from light; lyophilized stable at room temp short-term |
| Clinical trials | None completed โ preclinical stage |
| Research origin | University of Texas (Sabine Waschek et al.) |
5-Amino-1MQ dosing in research community protocols is extrapolated from preclinical animal studies. No human clinical trial dose has been established. The following reflects the current research community consensus โ not a clinical recommendation.
| Protocol | Dose | Frequency | Notes |
|---|---|---|---|
| Standard research (oral) | 50โ75mg/day | Daily or split AM/PM | Most common community protocol |
| Higher range (oral) | 100mg/day | Daily | Used in some protocols; limited justification |
| Preclinical animal equivalent | ~10โ50mg/kg/day | Daily | Allometric scaling gives rough 50โ100mg human equivalent |
| Protocol | Dose | Frequency | Notes |
|---|---|---|---|
| SubQ injection | 25โ50mg/day | Daily | Lower dose vs oral due to improved bioavailability |
Unlike most peptides where oral administration is impractical due to GI degradation, 5-Amino-1MQ as a small molecule survives GI transit reasonably well. Many researchers prefer oral dosing for convenience. SubQ is used for those who want more predictable systemic exposure with a lower dose requirement.
If using lyophilized powder for SubQ injection, reconstitute with bacteriostatic water. For a 50mg vial, add 2mL BAC water for a 25mg/mL concentration. At 25mg SubQ dose, that's 1mL (100 units on U100 syringe).
The landmark 5-Amino-1MQ studies from the Sabine Waschek group at UT showed that mice fed a high-fat diet and treated with 5-Amino-1MQ gained significantly less fat mass than controls โ without caloric restriction. Importantly, lean mass was preserved or slightly increased, suggesting the compound preferentially targets adipose tissue rather than causing generalized weight loss through wasting.
Treated animals showed measurable increases in resting oxygen consumption โ indicating higher basal metabolic rate. This is mechanistically consistent with NAD+ restoration improving mitochondrial efficiency in adipocytes, essentially making fat cells better at burning fat.
In vitro studies with preadipocytes (fat cell precursors) showed that 5-Amino-1MQ inhibits differentiation โ the process by which stem cells commit to becoming fat cells. This suggests the compound may limit expansion of fat tissue at the cellular level, not just burn existing fat.
Adipose tissue from 5-Amino-1MQ-treated animals showed significantly higher NAD+ levels and normalized SAM-to-SAH ratios compared to obese controls. The normalization of SAM/SAH ratio is particularly relevant because it reflects restored methylation capacity โ epigenetic machinery that regulates thousands of genes involved in metabolism.
Multiple studies showed improvements in insulin tolerance tests in obese animals treated with 5-Amino-1MQ, consistent with the metabolic improvements expected from NAD+ restoration and reduced adipose inflammation.
5-Amino-1MQ protocols in the research community typically run 8โ12 weeks with periodic breaks. The compound's mechanism โ enzyme inhibition rather than receptor activation โ means tolerance development is less of a concern than with receptor-based compounds, but cycling is still standard practice.
5-Amino-1MQ is commonly researched alongside other metabolic and fat-loss compounds given its unique upstream mechanism:
This combination has growing interest in the research community. Retatrutide drives significant caloric deficit and metabolic improvement via GLP-1/GIP/glucagon agonism. 5-Amino-1MQ targets adipose tissue metabolic machinery independently. The theoretical rationale for combining them is strong โ but direct combination research data does not yet exist.
5-Amino-1MQ has a limited human safety dataset โ no clinical trials have been completed. Safety data comes from preclinical animal studies and limited research community observations.
Unlike SS-31 (Phase 2) or Sermorelin (FDA-approved), 5-Amino-1MQ has zero completed human clinical trials. All safety inferences come from preclinical data. This is an important distinction when evaluating risk compared to compounds with established human safety profiles.
COA-verified vendor pricing with promo codes. Both S1 Research and Tegridy Research carry 5-Amino-1MQ.
View Pricing โ Dosage Calculator